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A simple, accurate, and precise HPLC method was developed and validated for determination of rimonabant in human plasma.
Followingliquid-liquidextraction,chromatographicseparationwasaccomplishedusingC18columnwithmobilephaseconsisting
of acetonitrile:water (90:10, v/v), drug was detected at 260nm using UVdetector. The LOD and LOQ were 3.0 and 10.0µg/L,
respectively. The method is linear in the interval 50.0–1000.0µg/L. The average extraction recovery of drug from plasma was
found to be 92.2%. The percent CV of the method was found to be less than 10.8%, and accuracy was found between 94.5 and
106.7%. The assay may be applied to a pharmacokinetic and bioequivalence study of rimonabant.
1.Introduction
Rimonabant (5-(4-chlorophenyl)-1-(2, 4-dichloro-phenyl)-
4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide,
Figure 1) is a neurokinin-3 antagonist and selective cannabi-
noid (CB1) receptor antagonist used for the management
of obesity [1, 2]. Rimonabant reduces the food intake and
increases the energy expenditure. These eﬀects are due to
inhibition of the CB receptors situated in the mesolimbic
area. They modulate the neurochemical activation of hypo-
thalamic neurons and the state of relative energy balance.
Rimonabant also inhibits the enzymes involved in lipogene-
sis [3]. Rimonabant has good oral bioavailability and long
duration of action (8 hours). The half-life varies in healthy
and obese individuals. In healthy adults with a body mass
index of 18 to 28kg/m2 receiving once-daily doses of ri-
monabant 20mg, the half-life ranged from 6 to 9 hours.
In obese individuals with a body mass index of >30kg/m2,
the half-life was longer (16 hours), due to the larger pe-
ripheral volume of distribution. Following multiple once-
daily doses of 20mg to healthy subjects in the fasted state,
maximum plasma concentrations of rimonabant are achi-
eved in approximately 2 hours, with steady state plasma
levels achieved within 13 days (C max = 196 ± 28.1µg/L;
AUC 0–24 = 2960 ± 268µg·h/L) [4]. Rimonabant appears
to increase the risk of suicidality and was not approved
by FDA. The EMEA (European Medicines Agency) has
recommended suspending the approval in Europe but the
drug may be remerged in tobacco and smoking-cessation
therapies. There were few LC-MS/MS method available for
the determination of rimonabant [5, 6]. These methods
may not be widely accessible due to their cost and ion
suppression/enhancement eﬀects, which may require expen-
sive sample and clean-up procedures. Here is a developed
economicalmethodwhichcanbeusedforthedetermination
of rimonabant from plasma.
2. Experimental
2.1. Materials and Reagents. Rimonabant API was supplied
by Cadila Healthcare Limited, Ahmedabad (India). Ace-
tonitrile (HPLC grade) was purchased from Qualigens Fine2 Journal of Analytical Methods in Chemistry
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Figure 1: Structure of rimonabant.
Chemicals, India. Methanol (HPLC grade) was purchased
from Rankem, RFCL Limited (India). Water was puriﬁed
using a Milli-Q system (YoungLin Basic 370 series).
2.2.ApparatusandChromatographicConditions. HPLCanal-
ysis was performed on YoungLin system equipped with qua-
ternary SP930D gradient pump, a vacuum degasser and
mixer, a UV730D UV/VIS detector, and a rheodyne injector
holding 20µL loop. The signals were acquired and ana-
lyzed using Windows XP-based YoungLin Autochro-3000
software. The separation of the compound (rimonabant)
was made on a Nucleosil-C18 column (250mn × 4.6mm,
5µm particle size) using isocratic elution. The ﬂow rate
was 1mL/min. UV detection was performed at 260nm
using mobile phase acetonitrile and water (90:10, v/v). Peak
identity was conﬁrmed by retention time (6.67min).
2.3. Preparation of Stock Solutions, Calibration Standard, and
Quality Control Samples. The standard stock solution of
rimonabant (1.0mg/mL) was prepared in acetonitrile. The
working standard solution (10µg/mL) was prepared by
diluting the stock solution in acetonitrile. A serial calibration
line of samples of concentration of 50, 100, 200, 300, 400,
500, and 1000µg/L of rimonabant was prepared by diluting
deﬁnitealiquotsofworkingstandardwithplasmaupto2mL
and then precipitated with 3mL of acetonitrile, followed by
centrifugation at 5000g at room temperature for 16min,
and the supernatant was ﬁltered with 0.22µm ﬁlter. The
quality control samples (low, medium, and high) were also
prepared by diluting standard solution with plasma to form
concentrations of 150, 450, and 800µg/L of rimonabant. A
calibration curve was made from a blank sample (a drug-free
plasma sample) and seven plasma-spiked samples with drug
covering the total range (50–1000µg/L). Such calibration
curves were generated on three consecutive days.
2.4.Speciﬁcity. Speciﬁcityofthemethodestablishedbyusing
six diﬀerent lots of plasma samples (4 normal lots, one hae-
molised, and one lipemic lot). In each plasma lot, blank
samples and LLOQ (lower limit of quantitation) were pro-
cessed and analysed as per assay procedure to determine any
signiﬁcant interference at the RT of analyte.
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Figure 2: Chromatogram of blank plasma.
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Figure 3: Chromatogram of low quality control sample.
2.5. Sensitivity. The limit of detection and limit of quantiﬁ-
cation were determined by calculating the S/N method, for
this LLOQ (lower limit of quantitation 50µg/L) is diluted
with plasma by serial dilution (50.0, 25.0, 10.0, 5.0, 3.0, 2.0,
1.0µg/L), processed and analysed in replicate sets with blank
samples and the % CV of the areas obtained is calculated.
2.6. Extraction Recovery. Recovery of rimonabant was evalu-
ated by comparing the mean peak areas of six-extracted low-
quality control samples with the mean peak areas of six neat
reference solutions containing the same amount of the test
compound (Figures 2 and 3).
2.7.PrecisionandAccuracy. Theintrabatch,interbatch,inter-
day, and analyst to analyst precision and accuracy of the
developed method were evaluated in plasma samples spiked
with rimonabant at each QC level. Intrabatch and interbatch
precisions and accuracies, and the samples that had been
spikedataconcentrationof150.0,450.0,and800.0µg/Lwere
assayed. The interday precision and accuracy were evaluated
on three consecutive days and two diﬀerent analysts evalu-
ated analyst-to-analyst precision.
2.8. Stability. The low QC and high QC samples (150 and
800µg / L )t r e a t e da ss a m p l ep r e p a r a t i o nw a sk e p ta tr o o m
temperature for 24 hours and then the stability was deter-
mined. The freeze-thaw stability was determined after three
repeated freezing and thawing cycles on day 0, 1, and 2. For
each concentration and each storage condition, six replicates
were analyzed in one analytical batch. The concentration ofJournal of Analytical Methods in Chemistry 3
rimonabantaftereachstorageperiodwasrelatedtotheinitial
concentration as determined for the samples.
3. Results andDiscussion
3.1. Development of LC Method. For optimum detection and
quantitationofrimonabantinhumanplasmabyliquidchro-
matography, it was necessary to maintain the chromato-
graphic condition throughout the experimentation. The ef-
fect of acetonitrile content in the acetonitrile/water mobile
phase on rimonabant retention time was investigated. As
expected in reversed-phase HPLC, increasing the water
content from 10 to 20% (v/v) resulted in a general increase
in retention time due to greater hydrophobic interaction
between the bonded alkyl stationary phase and the drug. A
mobile phase composed of acetonitrile water in a ratio of
90:10 (v/v) at ﬂow rate 1mL/min was used to complete
separation and detection of rimonabant by UV detector at
relatively low concentrations without interference of sample
matrixes. The high percentage of acetonitrile in the mobile
phaseallowsrapiddeterminationofdrugwithretentiontime
less than 7min. Figures 2 and 3 show the representative
chromatograms of blank plasma and plasma spiked with ri-
monabant at 0.050µg/mL.
3.2. Validation of LC Method
3.2.1. Speciﬁcity. Observed retention time for rimonabant
was found to be 6.67min. Plasma samples of diﬀerent lots
were found to be free from interfering substances at the
retention time of rimonabant, and there is no impact of hae-
molysis or lipemic plasma in peak detection.
3.2.2. Linearity, Limit of Detection, and Limit of Quantiﬁca-
tion. The most variable regression equation of calibration
curve was y = 0.0564x − 0.0318 (r2 = 0.9992) and the
acceptable minimum criterion of the correlation coeﬃcient
(r)m u s tb e= 0.99 [7], hence the correlation coeﬃcient
showed good linearity. The limit of detection (LOD) and
limit of quantitation (LOQ) of rimonabant in plasma
samples were determined to 3.0 and 10µg/L, respectively.
The calibration curve range is suitable to measure plasma
concentration proﬁle of the formulations, since it is covering
well enough the Cmax range (192 ± 28µg/L) reported in the
literature [4].
3.2.3.InaccuracyandImprecision. At otalo fﬁ v ebat c hesw e r e
testedfortheexperiments,andpercentofCVandinaccuracy
ranged from 4.3 to 5.1 and 97 to 101.9, respectively. Intra-
day, interbatch, interday, and analyst-to-analyst imprecision
showed a percentCV of 3.2 to 4.0, 3.4 to 3.7, 2.7 to 5.1, and
2.1to6.4%,respectively.Theinaccuracyofproposedmethod
was found between 94.5 to 106.7%. The data proved good
precision of the developed method. The results of intrabatch,
interbatch, interday, and analyst to analyst are illustrated in
Table 1.
Table 1: Imprecision and inaccuracy results of validation.
Spiked conc.
(µg/L)
Conc. found
mean ± SD
(µg/L)
CV (%) Accuracy (%)
Intraday imprecision and inaccuracy (n = 18)
150 151.8 ±6.00 4.0 101.2
450 442.3 ±19.51 4.4 98.3
800 780.6 ±25.30 3.2 97.6
Interbatch imprecision and inaccuracy (n = 12)
150 153.9 ±5.20 3.4 102.6
450 430.5 ±16.70 3.9 95.7
800 810.6 ±30.3 3.7 101.3
Interday imprecision and inaccuracy (n = 12)
150.0 156.4 ±8.04 5.1 104.3
450.0 435.2 ±17.90 4.1 96.7
800.0 756.2 ±20.45 2.7 94.5
Analyst to analyst imprecision and inaccuracy (n = 18)
150.0 160.0 ±10.30 6.4 106.7
450.0 458.3 ±9.80 2.1 101.8
800.0 780.2 ±24.90 3.2 97.5
Global imprecision and inaccuracy (n = 30)
150.0 152.9 ±6.60 4.3 101.9
450.0 436.4 ±22.05 5.1 97.0
800.0 795.6 ±36.59 4.6 99.5
Table 2: Extraction recovery of rimonabant from plasma (n = 6).
Analyte Conc. added
(µg/L)
Mean recovery
± SD (%) CV (%)
Rimonabant
150.0 93.9 ±12.00 8.5
450.0 91.3 ±22.20 5.4
800.0 91.3 ±14.60 2.0
The average global recovery = 92.2%, and percent CV of global recoveries =
1.6%.
3.2.4. Extraction Recovery. Protein precipitation was em-
ployed for the extraction of drugs from biological matrix,
that is, plasma, and acetonitrile is used as the precipitating
solvent because it shows the good recovery of drug from
the plasma (Table 2). Extraction of drug from plasma was
also tried with other organic solvents as precipitating agent,
namely, methanol and salt solutions (sodium sulphite) of
diﬀerent concentrations (12.6, 15.8, and 21%). The recovery
with methanol is comparable to acetonitrile, but 3mL of
methanol is needed for complete precipitation of 1mL of
plasma, which diluted the drug concentration in sample to
half as compared to acetonitrile. In case of salt solutions
as precipitating agent till 21% salt concentration followed
by centrifugation at 10000RPM for half an hour, clear
supernatant was not observed. Therefore, acetonitrile was
selected for extraction as it shows highest extraction recovery
with minimum dilution factor.4 Journal of Analytical Methods in Chemistry
Table 3:Benchtopandfreeze-thawstabilityofrimonabant(n = 6).
Nominal
conc. (µg/L)
Mean found conc. (µg/L) CV (%) CV (%)
Bench top
stability 0hrs 12hrs 24hrs 12hrs 24hrs
150.0 155.2 144.5 135.8 7.9 10.8
800.0 785.3 767.6 760.9 1.0 1.6
Freeze-thaw
stability Day 0 Day 1 Day 2 CV day
(%) 1
CV day
(%) 2
150.0 149.5 147.4 143.2 4.6 5.4
800.0 789.9 795.6 789.1 0.5 1.4
3.2.5. Stability. Twenty-four-hour room-temperature stor-
age and freeze-thaw cycles for low- and high-quality control
samples indicated that rimonabant was stable in human
plasma under experimental condition. Stability results are
illustrated in Table 3.
4. Conclusion
The HPLC method for determination of rimonabant in
human plasma has been developed. Method validation has
been demonstrated by a variety of tests for speciﬁcity, sen-
sitivity, linearity, precision, accuracy, recovery, and stability.
The validated interval (50.0–1000.0µg/L) is suﬃcient to
measure plasma concentration proﬁle of the formulations
havingadoseof20mginbioequivalencestudyobtained.The
result of analysis suggests the applicability, reproducibility,
andutilityofthemethodfordirectestimationofrimonabant
in plasma sample.
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